This Sources Sought opportunity from Department Of Health And Human Services was posted on June 3, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

RFI - Protection Before Day One Vaccine: Seasonal Influenza Vaccines with Pandemic Coverage

Closed

RFI-26-08-PBD1Federal

Submission Closed07/15/2026, 05:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Grant

Genomic Data Generation Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed)

Solicitation # RFA-RM-27-008

The National Institutes of Health, under the Department of Health and Human Services, is seeking applications for Genomic Data Generation Center(s) to support the Gabriella Miller Kids First Pediatric Research Program. The primary objective is the rapid production of high-quality sequence and variant data from human specimens related to pediatric conditions, specifically childhood cancers and congenital anomalies. Required data types include genome-wide, RNA, and long-read DNA and RNA sequencing, as well as chromatin accessibility data and genome-wide methylation profiling. All generated data will be re-processed and harmonized by the Kids First Pediatric Data Resource Center to maintain a public-facing, cloud-based resource for the research community. The NIH Common Fund intends to commit 5 to 6 million dollars annually for a maximum award period of three years, with an award ceiling of 3.5 million dollars. Applications are due by January 8, 2027, and will be evaluated via the NIH peer review system based on significance, investigator qualifications, innovation, and approach. A key requirement is the center's agility to implement new assays within a two-month timeframe. This opportunity is restricted to projects that do not propose clinical trials. Eligible applicants must maintain active registrations in SAM, eRA Commons, and Grants.gov. Awardees must adhere to strict cybersecurity protocols, including multifactor authentication and a 48-hour incident notification window, and comply with federal regulations 42 CFR Part 52 and 2 CFR Part 200. Proposals must include itemized per-sample costs, a minimum sample estimate, and a plan for cost reduction over the award period. All research involving human subjects must comply with 45 CFR Part 46, and a comprehensive Data Management and Sharing Plan is required at the time of application.

National Institutes Of Health

POSTED

DEADLINE

Health & Life Sciences Data ProviderThis subcontract opportunity with the Government of Canada seeks a Health and Life Sciences Data Provider to supply medical datasets and health-related information products. The selected provider will support prime contractors on Public Services and Procurement Canada projects by delivering pharmaceutical data, healthcare statistics, and clinical research information, as well as specialized life sciences reports. Interested parties must be capable of entering into a Provider’s Master License Agreement to facilitate the delivery of these datasets. The solicitation is open for responses until March 31, 2027, with the place of performance located within Canada.

Government of Canada / Gouvernement du Canada

POSTED

DEADLINE

Senior Advisor for Neurotherapeutic Network (Small Molecules)The Senior Advisor for Neurotherapeutic Network (Small Molecules) is a small business set-aside subcontract through the Department of Health and Human Services Omas Strategic Buying Center. The selected consultant will provide executive-level subject matter expertise to prime contractors supporting NIH NINDS Blueprint Neurotherapeutic Network projects. Primary responsibilities include reviewing program operations, offering strategic recommendations for pharmacology-related trials, and leading drug discovery teams focused on small molecules for nervous system conditions. Qualified candidates must possess a PhD in Pharmacology, an MD, or an advanced degree in Organic Chemistry. The role requires the delivery of high-level technical reports, detailed scientific analyses, and formal recommendations to meet project milestones. This opportunity was posted on October 28, 2026, with a response deadline of November 5, 2026, falling under NAICS code 541714.

Omas Strategic Buying Center - Professional Services

POSTED

DEADLINE

High-throughput Unmasking of Biological Interactomes with Binding Landscape Emulators (HUBBLE)

Solicitation # DARPA-PA-27-01

The High-throughput Unmasking of Biological Interactomes with Binding Landscape Emulators (HUBBLE) program, solicited by the DARPA Biological Technologies Office under DARPA-PA-27-01, seeks to develop an in-silico capability for mapping all protein-protein interactions. The primary objective is to create a comprehensive human interactome hypercatalog capturing over 10 million new interactions, shifting from static biomarkers to dynamic, context-aware interactomes. The utility of this capability will be demonstrated by identifying novel diagnostic and therapeutic targets for traumatic brain injury. Awards will be issued as Other Transaction (OT) for Research agreements with fixed, payable milestones. The program is structured in two phases, with Phase 1 estimated at 12 months and Phase 2 anticipated at 18 months, though current awards are limited to Phase 1. Proposers, including large and small businesses, universities, and research institutions, must submit a maximum six-page unclassified abstract via the Broad Agency Announcement Tool by November 5, 2026, to be considered for an Oral Proposal Package due December 11, 2026. Evaluation is based on technical comprehension, technical ability, and the realism of the cost rough order of magnitude. Prime proposers must be registered in the System for Award Management and demonstrate CMMC Level 1 compliance. Performance will be managed through a Task Description Document and a milestone-based payment schedule, with invoicing processed through the Wide Area Workflow system. Security requirements include the Fundamental Research Risk-Based Security Review Process for all senior and key personnel.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Pharmacology and Pain Drug Development SMEThis subcontract opportunity through the Department of Health and Human Services Omas Strategic Buying Center seeks a subject matter expert in pharmacology and pain to support prime contractors on NIH HEAL Initiative projects. The selected expert will provide executive-level guidance on small molecule and biologic therapeutics, focusing on drug discovery and pharmacology-related trials for nervous system conditions. Key responsibilities include performing strategic programmatic reviews, evaluating milestones, and providing mentorship. The role requires the delivery of strategic recommendations and milestone evaluations through formal committee reports. Performance will take place in Bethesda, and the opportunity is categorized under NAICS code 541714. Interested parties should note the response deadline of November 3, 2026.

Omas Strategic Buying Center - Professional Services

POSTED

DEADLINE

Precision Prevention & Biological Pathway ResearchThe Precision Prevention and Biological Pathway Research subcontract supports prime contractors on Defense Health Agency Alzheimer’s Research Program projects. The primary objective is to conduct research linking service-related exposures to AD/ADRD biological pathways by quantifying military-relevant risk factors. This technical work involves the use of proteomics tools and genomic sequencing to map these biological pathways, culminating in the delivery of detailed research reports and data. Performance of this contract takes place in Frederick, Maryland, under NAICS code 541714. Due to the nature of the study, the contractor must obtain IRB approval and maintain all necessary Human Subjects Research certifications. Interested parties should note the response deadline of December 4, 2026.

Defense Health Agency

POSTED

DEADLINE

Blood-Based Biomarker Validation & ScalingThis subcontract focuses on the validation and scaling of blood-based biomarkers to support prime contractors within the Defense Health Agency Alzheimer’s Research Program. The scope of work involves performing detailed laboratory analysis of blood samples, validating the sensitivity and specificity of assays, and establishing scalable testing protocols. These operations must utilize Simoa equipment and biobanking systems while adhering strictly to GLP standards and maintaining CLIA certification. The project is managed under the Department of Defense and is centered in Frederick, Maryland. The primary objective is the delivery of validated, scalable biomarker assays and protocols to advance research goals. Interested parties should note the response deadline of December 4, 2026, and the classification of the work under NAICS code 541714.

Defense Health Agency

POSTED

DEADLINE

RFI Alzheimer’s Research Program (AZRP) Public

Solicitation # HT9427RFI2027AZRP

The Defense Health Agency, through the Congressionally Directed Medical Research Programs, has issued a Request for Information under solicitation number HT9427RFI2027AZRP to gather strategic feedback for the fiscal year 2027 Alzheimer’s Research Program. The primary objective is to identify research focus areas and funding opportunities aimed at mitigating the impact of Alzheimer's and related dementias, specifically those associated with traumatic brain injury, military service, and diverse risks. The program seeks to improve the quality of life for Service Members, Veterans, and their families by funding solution-oriented research, including the development of digital and blood-based biomarkers for early diagnosis and the creation of precision prevention strategies. This action is strictly for information and planning purposes and does not constitute a formal solicitation, request for proposals, or request for quotations. No contracts will be awarded based on this announcement, and FY27 funds have not yet been appropriated. Interested parties from academia, industry, non-profit organizations, and federal agencies are invited to provide feedback via Survey Monkey by December 4, 2026. Respondents are cautioned not to submit proprietary or sensitive information through the survey portal as it cannot be protected. The effort is categorized under NAICS code 541714 and is managed by the Department of Defense in Fort Detrick, Maryland.

Defense Health Agency

POSTED

DEADLINE

Traumatic Brain Injury and Psychological Health Research Program Public Request for Information

Solicitation # HT9427RFI2027TBIPHRP

The Defense Health Agency, under the Department of Defense and the Congressionally Directed Medical Research Programs, has issued a Request for Information under solicitation number HT9427RFI2027TBIPHRP. This action is strictly for strategic planning and is not a formal solicitation, request for proposals, or request for quotations. The primary objective is to gather feedback from academia, industry, non-profit organizations, and the public to inform the research focus areas and funding opportunities for the fiscal year 2027 Traumatic Brain Injury and Psychological Health Research Program. The program aims to optimize the prevention, assessment, and treatment of psychological health conditions and traumatic brain injuries to benefit Service Members, Veterans, and the general public. Interested parties are asked to provide input on research gaps and funding priorities, specifically regarding the prevention, screening, diagnosis, and treatment of these conditions. Responses must be submitted via Survey Monkey by December 11, 2026. Because the government cannot protect proprietary or sensitive information submitted through the survey platform, such data should not be included. This inquiry does not commit the program to incorporating the feedback into future funding opportunities, and no contract will be awarded based on this specific announcement. All inquiries regarding this RFI should be directed to Patrick M. Younkins.

Defense Health Agency

POSTED

DEADLINE

Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Solicitation # 75A50126R00001_RFP_NPIVS_27

The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. The objective is to maintain a permanent readiness posture against high-threat influenza and other viruses with pandemic potential. Selected contractors will provide essential services, personnel, and facilities to produce vaccines, antigens, and adjuvants, while generating the necessary analytical, nonclinical, clinical, and chemistry, manufacturing, and controls data for FDA submission to support rapid regulatory decisions. To be eligible, offerors must be capable of producing vaccines against influenza strains with pandemic potential and demonstrate success through a U.S. influenza vaccine license or a submitted Biologics License Application. The government intends to award contracts to four offerors based on the Highest Technically Rated Offerors with a Fair and Reasonable Price methodology. Evaluation focuses on capabilities, past performance, and price, with a minimum requirement of a High Confidence rating for technical capabilities. The contract structure consists of a 60-month base period and a 60-month option period, with a minimum guarantee of 50,000 dollars. Key requirements include the development of comprehensive manufacturing and business continuity plans, adherence to strict ASPR security and cybersecurity standards, and the use of the Department of Treasury Invoice Processing Platform for quarterly invoicing. Performance is monitored through a BARDA dose tracker, and final acceptance is triggered by the submission of a final report and updated dose tracking data.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

USDA SBIR/STTR Topic 8.2 — Plant Production and Protection - Biology

Solicitation # USDA-NIFA-TOPIC-8.2

The USDA National Institute of Food and Agriculture is soliciting proposals under Topic 8.2 for Plant Production and Protection - Biology. This initiative focuses on advancing crop production and protection through the development of innovative plant breeding methods, diagnostic technologies for diseases, and the creation of new food and non-food crop plants. Research efforts are directed toward improving plant characteristics to mitigate biotic and abiotic stresses, developing new genotypes for commercial applications, and creating tools to support the health of natural and domesticated pollinators. This opportunity is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to companies with fewer than 500 employees. Managed by the United States Department of Agriculture, the program is led by Dr. Christopher Philips. Interested parties can find further details and application guidelines through the NIFA website.

National Institute of Food and Agriculture

POSTED

DEADLINE

Quantitative Analysis of Longitudinal MR Images

Solicitation # 75N98027R00005

Solicitation 75N98027R00005 is a Sources Sought notice issued by the National Institute on Aging (NIA) to identify qualified companies capable of performing quantitative analysis of longitudinal Magnetic Resonance (MR) images. The project supports the Baltimore Longitudinal Study of Aging (BLSA) by processing 300 newly acquired MR datasets to characterize brain aging trajectories and identify predictors of cognitive decline and Alzheimer’s disease. The selected contractor will provide specialized, non-commercial services to deliver global and regional tissue volumes, lesion quantification, and machine learning-derived scores, such as SPARE-AD, while ensuring longitudinal consistency with data acquired since 1994. The anticipated contract will be a firm fixed price award with a period of performance of one year. Key deliverables include quantitative volumetric results, intermediate processing files, and registration maps for PET overlay, submitted every six months, concluding with a final report. Technical requirements emphasize the use of established image analysis tools and adherence to FISMA/FedRAMP-aligned data security controls to protect participant confidentiality. Interested respondents must submit a capability statement by November 9, 2026, to Contract Specialist Sneha Singh. The submission must be limited to ten pages and include the company's Unique Entity ID, NAICS code 541714, professional qualifications of personnel, and any applicable GSA schedules or government-wide acquisition contracts. Small businesses are encouraged to respond to this market research effort to help the government determine the appropriate acquisition method.

National Institutes Of Health Olao

POSTED

7 days ago

DEADLINE

in 11 days

AI Contract Overview

The Center for Biomedical Advanced Research and Development Authority (BARDA) is seeking information on vaccine candidates designed to provide dual protection against seasonal influenza and emerging pandemic influenza strains, referred to as “Day One vaccines.” These vaccines aim to bridge the critical three-month gap between the emergence of a novel pandemic strain and the availability of strain-matched vaccines, offering immediate, albeit partial, immunity to reduce infection rates, hospitalizations, and peak transmission during the earliest phase of a public health emergency. The desired profile includes seasonal flu protection alongside cross-reactive immunity against high-priority avian subtypes such as H2, H5, H7, and H9, with minimal requirements including at least a 10% reduction in pandemic infections and 30% reduction in hospitalizations, while ideal characteristics involve broader coverage across all influenza A subtypes, multiyear durability, room-temperature stability, and safety comparable to current seasonal vaccines. Responses are sought from organizations capable of demonstrating technical maturity in vaccine design, nonclinical and clinical data supporting efficacy and immunogenicity against both seasonal and pandemic strains, readiness in manufacturing and CMC processes, and a clear regulatory strategy aligned with FDA pathways. This Request for Information (RFI-26-08-PBD1), posted on June 3, 2026 and due by July 15, 2026, is strictly a market research tool with no intent to award a contract or provide compensation for submissions. Respondents must submit a single PDF document not exceeding ten pages, with strict section limits outlined for executive summary, organizational overview, vaccine candidate details, nonclinical and manufacturing data, clinical strategy, and regulatory considerations. The submission must be emailed to [email hidden] by the deadline, with no other formats or attachments permitted. While no formal contract clauses or payment terms are included, respondents are required to self-identify as small or other-than-small businesses under NAICS code 541714, and submissions must be clearly marked for confidentiality if they contain proprietary information. All information provided may be reviewed by non-federal personnel under NDA, and future awards may require membership in the RRPV consortium. The primary performance location is Washington, DC, and any subsequent procurement will evaluate technical superiority over cost, prioritizing innovation, breadth of protection, manufacturability, and public health impact to enable rapid deployment of a vaccine that offers meaningful protection from Day One of a pandemic.

General Info

Seeking development of immediate, dual-benefit influenza vaccines to bridge early pandemic protection gap.

Agency

Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Washington, DC, 20024, USA

Set-Aside

NONE

Documents

RFI-26-08-PBD1 Protection Before Day One Vaccine RFI

rfi

High

AI Contract Breakdown

Uniform Contract Format

Timeline

PhaseClosed

PostedJun 3

Sources Sought

Response DeadlineJul 15

Deadline has passed

Submission Closed

07/15/2026, 05:00:00 PM UTC

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Contacts1 person available

OfficeWASHINGTON, DC, 20515, USA

Organization / AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Office AddressWASHINGTON, DC, 20515, USA

Contacts

Wendy Rehman

contact@example.gov

Full Description

“Protection Before Day One Vaccine: Seasonal Influenza Vaccines with Pandemic Coverage”

Request for Information (RFI)

1.0 Background

Influenza viruses remain a persistent and evolving threat to public health in the United States and globally. Seasonal influenza epidemics cause significant morbidity and mortality each year, while novel zoonotic influenza subtypes retain the potential to trigger pandemics. A critical vulnerability in current pandemic preparedness is the time required—typically at least three months—between identification of a novel pandemic strain and deployment of strain-matched vaccines at scale.

The Center for the Biomedical Advanced Research and Development Authority (BARDA) has led efforts to develop improved influenza vaccines and expand domestic manufacturing capacity, including initiatives to accelerate vaccine development timelines. However, limitations in current vaccine technologies result in a protection gap during the earliest phase of a pandemic.

In a pandemic setting, early intervention is crucial to dampening the spread and impact of a novel virus. Prior modeling studies have demonstrated that a modestly effective but rapidly distributed vaccine can provide a greater benefit than a highly efficacious but delayed vaccine. Similarly, bolstering population immunity before a pandemic would lessen the damage caused by emergent influenza strains, even if the vaccine is only partially protective. BARDA refers to these vaccines as offering “Protection Before Day One”, with “Day One vaccines” providing some degree of protection at the outset of a pandemic. Day One vaccines, would:

Deliver seasonal influenza protection; and
Provide partial protection against emerging pandemic influenza viruses at the onset of a Public Health Emergency.

Modeling suggests that Day One vaccines can not only reduce the total number of infections and peak infection rate but also delay the peak to allow more time for strain-matched pandemic vaccines to become available. In addition to the population-level benefits, Day One vaccines would also benefit individual vaccine recipients by reducing the risk of severe disease. Even with modest effectiveness, receiving a Day One vaccine could reduce an individual’s hospitalization risk by 35%.

Through this RFI, BARDA seeks to understand the availability of candidate Day One vaccines, including their development maturity, technical feasibility, manufacturing readiness, and regulatory considerations associated with vaccine candidates intended to meet this dual-benefit profile.

Please see full Request for Information attached.